The total volume of online sales and reservations of pharmacy assortment products (medicines and parapharmaceuticals) reached 408.7 billion rubles in Q1–Q3 2025 (at end-consumer prices, including VAT). The ruble-denominated growth rate versus Q1–Q3 2024 amounted to 34.5%, slightly below the pace recorded for Q1–Q2 2025, yet still substantially higher than the overall revenue growth rate of Russian pharmacies. According to the “Retail Sales Audit of Medicinal Products in Russia (total sell-out)” database by analytics company RNC Pharma, total pharmacy revenue increased by only 11.8%. Notably, parapharmaceutical sales in pharmacies not only failed to grow in Q1–Q3 2025 but even declined by 2%, equivalent to roughly 7 billion rubles in absolute terms—losses directly attributable to the active expansion of marketplaces.

The combined market share of the online channel, including reservations, amounted to 24% of total market volume in Q1–Q3 2025 (in ruble terms). This is more than four percentage points higher than in January–September 2024; however, the improvement is largely due to high activity during Q4 2024 and Q1 2025. Despite strong current dynamics, the segment’s share is not undergoing dramatic structural expansion at this stage. Growth within the e-commerce channel is also uneven: the most dynamic segment is home-delivery sales of medicinal products. In the period under review, the ruble volume of these sales grew by 48%, while physical volume increased by 3.5%. The ratio of these indicators clearly shows that the delivery channel concentrates primarily on higher-margin positions with above-average price points. Total consumer-delivery sales of medicinal products reached 15.4 billion rubles in Q1–Q3 2025, corresponding to approximately 1.13% of the overall Russian pharmaceutical market; year-on-year this share increased by 0.25 percentage points.

Among the top twenty e-commerce players, no radical shifts have occurred thus far. The fastest-growing project continues to be Polza.ru, operated by the company Puls, whose sales increased 2.3-fold in ruble terms. Notably, this structure is also the absolute leader in terms of expanding its pharmacy-partner base: in Q3 2025 alone the number of partner pharmacies grew by more than 4.1 thousand, bringing the total to 37.16 thousand. The second-strongest growth rate is demonstrated by Yuteka (+81%), which currently ranks fourth by revenue. Comparable dynamics are observed for the online division of Planeta Zdorovya (+72%), though the company has not yet entered the top ten. The most intense competition is unfolding for second place: Rigla currently holds the position, significantly increasing revenue through recent acquisitions, although its overall e-commerce growth rate (+29%) remains below the channel average. Meanwhile, Aprel is demonstrating online-segment growth of 51% and, if current trends persist, is a strong contender for second place overall.

Table. TOP-20 Pharmacy Chains and Alliances by Share of Sales Through Their Own Online Services, Q1–Q3 2025